The growing threat of untreatable fungal infections represents a blind spot in global health preparedness that could undermine decades of medical progress. Unlike bacterial resistance, which commands significant research funding and policy attention, drug-resistant fungi operate in relative obscurity despite causing over 1.5 million deaths annually worldwide. This oversight becomes increasingly perilous as immunocompromised populations expand through cancer treatments, organ transplants, and aging demographics. The call for antifungal resistance to receive formal recognition in updated antimicrobial resistance frameworks reflects mounting evidence that current therapeutic options are failing against evolving fungal pathogens. Candida auris exemplifies this crisis, spreading rapidly across healthcare systems while demonstrating resistance to multiple antifungal drug classes simultaneously. The pathogen's ability to persist on surfaces and transmit between patients has transformed routine medical procedures into potential exposure events. Beyond hospital settings, agricultural antifungal use creates selection pressure that may accelerate resistance development in environmental fungi capable of human infection. The limited antifungal arsenal compounds these challenges, with only four major drug classes available compared to dozens of antibacterial options. This therapeutic poverty stems partly from the evolutionary similarity between fungal and human cells, making selective toxicity difficult to achieve. Unlike bacterial infections where rapid diagnostic advances enable targeted treatment, fungal diagnosis often requires days or weeks, during which empirical broad-spectrum therapy may inadvertently select for resistant strains. The integration of antifungal resistance into global health policy frameworks would catalyze research into novel therapeutic targets, improve surveillance systems, and establish stewardship programs specifically designed for antifungal agents rather than adapting bacterial models.